Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘AdVise trial of brincidofovir’

Chimerix: An Intriguing Near Term and Long Term Outlook for the Stock (CMRX, Buy, $5.67)

Investment Thesis in Brief I am recommending purchase of Chimerix at the current price. The failure of brincidofovir in the phase 3 SUPPRESS trial for prevention of cytomegalovirus infections in hematopoietic stem cell patients has caused investors to write off the company and has resulted in a depressed stock price. To illustrate, I estimate that […]

Chimerix: Upgrading the Stock to a Buy (CMRX. Buy, $6.10)

Definitions of Key Words This section defines a number of words, phrases and acronyms that I have used in this report that may be useful for investors who may not have already done extensive research on Chimerix. virus: A virus is a small, non- bacterial, infectious agent that replicates only inside the living cells of […]

Chimerix: An Update (CMRX, $52.83, Neutral)

Company Description Chimerix is focused on the development and commercialization of antiviral drugs. Its lead product brincidofovir is a phospholipid derivative of Gilead’s existing anti-viral agent cidofovir. The differentiating feature is a much improved side effect profile that will allow much greater use of brincidofovir for treating infections caused by double stranded viruses, notably cytomegalovirus, […]